The journey to clinical remission of severe eosinophilic asthma: the combinatory role of type 2 inflammation biomarkers - Amsterdam 2025

Biologics in severe asthma

Chair(s): Fabio L. M. Ricciardolo, Sabina Skrgat

Session type: Poster session

The journey to clinical remission of severe eosinophilic asthma: the combinatory role of type 2 inflammation biomarkers

Akter Dilroba

EVENTS HOME

Poster
Abstract

Previous presentation

Next presentation

Session content

Sputum differential cell count profiles in severe asthma treated with tezepelumab

Gaël Tavernier

Poster

Abstract

Age-related differences in severe asthma patients addressed to biologics: insights from the SHARP Collaboration

Stefania Principe

Poster

Abstract

Real-World Impact of Mepolizumab on Mucus Plug Reduction in Severe Eosinophilic Asthma

Ebymar Arismendi

Poster

Abstract

Evaluation of the effectiveness of Dupilumab in patients with Severe Asthma using Forced Oscillation Technique (FOT): real-life data

Greta Insalata

Poster

Abstract

Clinical remission with biologics in severe asthmatics is not affected by age

Lorena Gentile

Poster

Abstract

Impact of endoscopic techniques on the management of patients with severe asthma eligible for biological therapy

Carmen Lores Benavente

Poster

Abstract

Does small airway disease (SAD) have an effect on the response to Tezepelumab?

Luca Paita

Poster

Abstract

Tezepelumab (anti-TSLP) effectiveness in real-life in Severe Asthma

Elisa Bentivegna

Poster

Abstract

Benralizumab affects specific compartments in severe asthma patients with chronic rhinosinusitis and nasal polyposis

Claudio Candia

Poster

Abstract

The journey to clinical remission of severe eosinophilic asthma: the combinatory role of type 2 inflammation biomarkers

Akter Dilroba

Poster

Abstract

Identification of severe eosinophilic asthma in patients with chronic rhinosinusitis with nasal polyps (CRSwNP) awaiting functional endoscopic sinus surgery

Drew Davies

Poster

Abstract

Alveolar Nitric Oxide as a Potential Biomarker for Assessing Airflow Obstruction Resolution in Severe Asthma Patients on Biologic Therapy

Tommaso Pianigiani

Poster

Abstract

The effect of biologics in the treatment of severe asthma- analysis of an age and sex matched cohort

Fabienne Jaun

Poster

Abstract

Does FEV1 stability tell us everything about lung function in asthma remission?

Francesca Cefaloni

Poster

Abstract

Small Airway Dysfucntion in Severe Asthma: Impact on achieving Clinical Remission

Mona Al-ahmad

Poster

Abstract

FeNO 350: A significant predictor of clinical remission in severe asthma

Flogerta Sana

Poster

Abstract

Tezepelumab in Uncontrolled Severe Asthma: A 3-Month Study on Small Airway Function and Symptom Control

Ourania Kotsiou

Poster

Abstract

Real-world Severe Asthma Registry in Latin America (REAL): Clinical features, phenotypes and treatment accessibility

Ignacio Zabert

Poster

Abstract

Clinical profile and characteristics of hospitalised severe asthma exacerbation patients on biologics

Gabriel Chen

Poster

Abstract

Biomarker predictors of biologic therapy response in patients with severe asthma and Aspergillus-IgG positive serology

Christine Chiang

Poster

Abstract

CDN Connection Issue

The ERS Congress 2025, Amsterdam

#{title}